Dr. Sarbajit Mukherjee, MD
Claim this profileRoswell Park Cancer Institute
Studies Esophageal Cancer
Studies Cancer
13 reported clinical trials
24 drugs studied
Area of expertise
1Esophageal Cancer
Stage IV
Stage III
HER2 positive
2Cancer
Stage IV
Stage III
RAS positive
Affiliated Hospitals
Clinical Trials Sarbajit Mukherjee, MD is currently running
Neratinib + TDxD
for Esophageal and Stomach Cancer
This trial is testing a combination of two drugs, Neratinib and TDxD, in patients with advanced stomach cancer that overexpresses HER2. These patients have not responded to previous treatments. The drugs work by blocking cancer growth and directly killing cancer cells.
Recruiting1 award Phase 119 criteria
Nivolumab + Standard Treatment
for Stomach and Esophageal Cancer
This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Adding nivolumab to ramucirumab and paclitaxel may work better to treat patients with advanced stomach or esophageal cancer.
Recruiting1 award Phase 2 & 320 criteria
More about Sarbajit Mukherjee, MD
Clinical Trial Related4 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Sarbajit Mukherjee, MD has experience with
- Nivolumab
- Pembrolizumab
- Fluorouracil
- Leucovorin
- Oxaliplatin
- Paclitaxel
Breakdown of trials Sarbajit Mukherjee, MD has run
Esophageal Cancer
Cancer
Adenocarcinoma
Colorectal Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sarbajit Mukherjee, MD specialize in?
Sarbajit Mukherjee, MD focuses on Esophageal Cancer and Cancer. In particular, much of their work with Esophageal Cancer has involved Stage IV patients, or patients who are Stage III.
Is Sarbajit Mukherjee, MD currently recruiting for clinical trials?
Yes, Sarbajit Mukherjee, MD is currently recruiting for 7 clinical trials in Buffalo New York. If you're interested in participating, you should apply.
Are there any treatments that Sarbajit Mukherjee, MD has studied deeply?
Yes, Sarbajit Mukherjee, MD has studied treatments such as Nivolumab, Pembrolizumab, Fluorouracil.
What is the best way to schedule an appointment with Sarbajit Mukherjee, MD?
Apply for one of the trials that Sarbajit Mukherjee, MD is conducting.
What is the office address of Sarbajit Mukherjee, MD?
The office of Sarbajit Mukherjee, MD is located at: Roswell Park Cancer Institute, Buffalo, New York 14263 United States. This is the address for their practice at the Roswell Park Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.